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Abstract 
Background: Breast cancer burden is on the increase in the developing world. Breast-conserving 
therapy (BCT) is prescribed for early breast cancer. It is the wide local excision of the tumour 
usually followed by radiation treatment to the breast. It is the mainstay treatment for carefully 
selected patients with early breast cancer presenting to the Groote Schuur Hospital’s Oncology and 
Endocrine Surgical unit, Cape Town South Africa. There has not been a formal audit to review the 
outcomes of BCT in the unit.  
Objectives: The objective of this study is to determine and analyse the excision margins for all the 
wide local excisions and the re-excision and local recurrence rates during the study period.     
Methods: This is a histopathological and oncology records review of the patients that have 
undergone BCT in the unit from the 1st of January 2006 until the 31st of December 2010. The 
University of Cape Town’s Faculty of Health Sciences Human Research Ethics Committee granted 
approval. Data points accrued included patient age, pathological tumour size and nodal status, 
histological tumour type, oestrogen receptor status, presence of lymphovascular invasion, volume of 
specimen excised, margin status, management of involved or close margins, completeness of 
radiotherapy, ipsilateral breast recurrence rate and total duration of follow up.   
Results: A total of 192 patients had BCT during the study period. The mean age is 53 years (range 
25 to 84 years). A median of 229.5 cm3 volume of specimen was excised (range 4 cm3 to 10530 
cm3). Infiltrating ductal carcinoma was the commonest histological type at 79.1%. 42.7% were pT1 
tumours, 49.0% pT2 tumours and 2.6 % pT3. The resection margin status are: positive margins rate 
of 15.1%, 8.3 % close margin (≤ 1 mm), 35.9% 1 – 5 mm, 23.4% 6 – 10 mm and > 10 mm 17.2%. 
An overall of 26 (13.5%) patients underwent a repeat surgical procedure. 16 (8.3%) had re-excision 
ix 
and 10 (5.2%) had a mastectomy. Residual tumour was present in 50% of the re-excisions and 
63.6% of mastectomies. As per category of the resection margins, 68.9% of patients with positive 
margins had repeat surgery (48.3% re-excision and 20.6% mastectomy). 31.1% of patients with 
positive margins did not have repeat surgery despite the indication due to advanced age, loss to 
follow up or residual tumour on the deep chest wall margin. 80.8% patients completed radiotherapy 
treatment post breast-conserving surgery. At a median follow up of 60 months (range 1 to 108 
months), a total of 11 (6.8%) patients had ipsilateral breast local recurrence. Median time to 
recurrence is 39 months (range 12 to 106 months).  
Conclusion: Positive and close margin re-excision and local recurrence rates in our unit are 
acceptable and comparable to other units in South Africa and internationally.  
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Chapter 1 - Introduction and Literature review 
Breast cancer affects 1 million women in the developed world every year [1]. The burden of breast 
cancer is also on the rise in the developing world. According to Jones [2], it is estimated that 70% of 
new cancer cases will occur in the developing world by the year 2020. 
 
Until the 1970s, the Halsted radical mastectomy had been the surgical procedure in the management 
of breast cancer irrespective of size. It was described and performed by William Stewart Halsted in 
1882 [3]. It included the excision of the skin, the breast and underlying pectoralis muscles. Patients 
also underwent an axillary lymph node dissection. A skin graft was often used to close the wound 
defect.  Patients were left with morbid disfiguring appearances.  
 
Modified radical mastectomy was shown to be as effectual as radical mastectomy and less 
mutilating. Modified radical mastectomy remains to be applicable to certain patients. However, BCT 
has become the adopted procedure for the surgical management of early breast cancer. BCT refers to 
the surgical excision of the primary breast cancer tumour with a rim of normal breast tissue, 
followed by radiation therapy. It is also referred to in the literature as lumpectomy, partial 
mastectomy or segmental mastectomy [4]. 
 
Over the past forty years prospective large multicentre randomized controlled trials (RCTs) in 
Europe and United States have provided level 1 evidence that there is no statistically significant 
difference in the overall long-term survival between mastectomy and BCT in appropriately selected 
patients treated for early breast cancer [5]. Although the overall long-term survival is similar between 
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the two procedures, patients undergoing BCT are at a recognized risk of ipsilateral breast tumour 
recurrence [6]. The success rate of BCT relies upon appropriate patient selection, surgical technique, 
and postoperative radiotherapy to eliminate microscopic tumour cells in the ipsilateral breast. The 
goals of BCT are therefore to resect the tumour with clear microscopic margins and to achieve 
acceptable cosmetic outcomes without compromising patient survival.  
 
The American College of Radiology and the American College of Surgeons provide a general 
framework for BCT [4]:  
• Single focal cancer is most desirable 
• Diffuse, malignant-appearing micro calcification on pre-operative mammogram contradicts 
BCT. This frequently correlates with diffuse ductal carcinoma-in-situ (DCIS), precluding the 
ability to achieve negative margins [7] 
• Prior therapeutic chest radiation therapy is a contraindication 
• Radiation treatment during pregnancy is a contraindication due to foetal safety concerns. 
Surgery can be done during pregnancy and radiation therapy completed after the delivery. 
• Connective tissue disease is a relative contraindication due to enhanced radiation toxicity. 
• Failure to clear margins after multiple repeated excisions is a contraindication to further BCT 
• Large tumour to breast size ratio is contraindication 
• Patient’s choice should be respected 
 The following are not contraindications to BCT: Family history, age, histological subtypes other 
than infiltrative ductal carcinoma, extensive intraductal component, involved lymph nodes in the 
axillar, tumour location, high risk of systemic relapse and dense breast tissue [4]. 
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BCT has become the standard of care in our surgical oncology/endocrine unit for patients meeting 
the above criteria diagnosed with early breast cancer at Groote Schuur Hospital. There has not been 
a formal audit to review the outcomes of BCT in the unit. In South Africa, there has been only one 
retrospective study on BCT. In 2005, Mannell, a part-time staff member at the University of 
Witwatersrand, published a retrospective review of 165 patients that underwent BCT at her private 
practice at Linksfield and Parklane Clinics over a period of 12 years. In her series 10 (6%) patients 
had close/involved margins, 7 patients had re-excision, 3 patients had mastectomy post the primary 
WLE. At a median of follow-up of 65 months, disease recurrence occurred in 9 (5.5%) patients [8]. 
 
The oncological safety of BCT in early breast cancer has been proven in many prospective 
randomized clinical trials (RCTs) that compared it to modified radical mastectomy [9-15].  
 
Fisher et al randomized 1851 patients whose tumours sized less than 4 cm and clinically node-
negative axillae in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial to 
receive modified radical mastectomy, lumpectomy alone, or lumpectomy with postoperative 
irradiation of the breast without extra boost to the lumpectomy site. All patients with histologically 
positive axillary lymph nodes received chemotherapy. The overall survival and disease-free survival 
at 20 years follow up were the same in all three-treatment arms. Local cumulative incidences of 
recurrence rate were 14.3% in women treated with lumpectomy and radiation therapy and 39.2% in 
women treated with lumpectomy alone (p value < 0.001) [9]. The patients with microscopically 
involved margins were managed with a mastectomy [9].  
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In the Milan I Trial, Veronesi et al randomized 701 women with tumours of up 2 centimetres and 
clinically node-negative axillae to radical mastectomy and BCT in the form of quadrantectomy with 
axillary dissection and postoperative radiation from the year 1973 to 1980 [10]. Patients with 
pathologically involved nodes received chemotherapy. Similar to the above study (NASBP B-06), at 
20 years follow up, the overall survival was the same between the two groups. There was a 
statistical difference in the crude cumulative recurrence incidence between the two surgical groups. 
Women who underwent quadrantectomy had a recurrence of 8.8% compared to 2.3% of women that 
had radical mastectomy (p value < 0.001) [10]. Recurrence was found to be high in younger females 
below the age of 45 years. The authors attributed this to the multifocality and multicentricity of 
breast cancers in the younger women. The authors further concluded that the survival is determined 
by metastases and not by the extend of surgery. Patients with intraductal non-invasive carcinoma 
were excluded from the trial [10]. 
 
In the European Organization for Research and Treatment of Cancer (EORTC) Trial 10801 
conducted from May 1980 to May 1986, 868 patients with American Joint Committee on Cancer 
(AJCC) stage I and II breast cancer were randomized to BCT or modified radical mastectomy across 
8 centres in the United Kingdom, Netherlands, Belgium, and South Africa [11]. In this trial, BCT 
constituted excision of the cancerous lump with a macroscopic margin of at least 1 cm and axillary 
dissection. This was followed by radiation dose of 50 Gy and 25 Gy boost to the tumour bed. In 
contrast to the NSABP B-06 and Milan I trials, the EORTC 10801 included larger tumours of up to 
5 cm. At 10-year follow-up, van Dongen et al reported a difference in loco regional recurrence rate 
favouring the modified radical mastectomy group (11.8% versus 19.7% for patients assigned to 
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BCT; P=0.0097) [11]. The recurrence rate for complete excision and positive margin was 17.6% and 
26.5% respectively. The median time to local recurrence was reported at 3.9 years after BCT. 
However, it is important to note that the excision margins were not routinely inked to assess the 
microscopic completeness of the lumpectomy, and that there were no instructions in their protocol 
for re-excision. Re-excision took place only when macroscopic disease was let behind [11]. 
 
Litière et al showed that at twenty-year follow-up of the EORTC 10801 trial, distant metastases-free 
survival and overall survival rates did not show any significant difference between BCT and 
mastectomy groups [12]. They further demonstrated on a multivariate that clinical tumour size >2 cm, 
lymph node metastasis and age greater than 50 were associated with increased rates of death, 
independent of treatment group, with hazard ratios of 1.35 (p value = 0.013), 1.88 (p value <0.0001) 
and 1.50 (p value <0.0001) respectively [12].  
 
In the institute Gustave-Roussy Breast Cancer Group trial, 179 women with tumours less than 2 
centimetres were randomized to modified radical mastectomy versus lumpectomy [13]. All of their 
patients had frozen section of the axillary lymph nodes. The patients with nodal metastases were 
further randomized to lymph node irradiation versus no further regional treatment. The results show 
that overall survival, distant metastasis, contralateral breast cancer, new primary malignancy, and 
loco regional recurrence rates were not significantly different between the two surgical groups, or 
between lymph node irradiation groups at fifteen years of follow up. Local recurrence rate at 15 
years was 9% and 14% in the BCT and mastectomy groups respectively. This difference was not 
statistically significant [13].   
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The National Cancer Institute in the USA trial randomized 237 patients with AJCC clinical stages I 
and II breast cancer to modified radical mastectomy versus lumpectomy, axillary dissection, and 
radiation therapy between the year 1979 and 1987 [14]. At 10 years follow up, no statistical 
difference in survival and recurrence rates between the mastectomy and BCT patients [14]. 
 
The Danish Breast Cancer Group trial randomized 904 patients with invasive cancer to modified 
radical mastectomy versus quadrantectomy wide local excision from January 1983 until March 1989 
[15]. At 6 years, survival was not statistically significant between the two groups [15]. 
 
Risk factors for ipsilateral breast tumour recurrence in BCT 
 
A number of pathological, clinical and treatment-related factors have been studied to identify 
patients that are at risk of ipsilateral breast tumour recurrence. Identifying risk factors for recurrence 
after BCT will help to optimize the management of patients.  
 
Pathological Features 
 
1. Margin Status 
The resection margin status is defined as the closest microscopic distance between the inked 
lumpectomy tissue edge and any cancerous tissue, be it invasive or carcinoma in-situ [7]. Therefore, 
7 
obtaining a negative excision margin is considered a basic prerequisite for standard-of-care BCT [16]. 
Pathologic margin status is the most established factor for predicting local recurrence after BCT [6]. 
There is a general agreement that if the surgical margins are positive, there is a very high risk of 
local recurrence. However, assessment of the final margin status is influenced by a number of 
factors such as the method of excision, the method of identifying specimen margins (orientation and 
inking of true margins), thoroughness of the pathologic assessment (number of histologic sections 
evaluated), and the definition of what constitutes a positive, negative, or close pathologic margin [6]. 
Local recurrence rate has been reported between 6 to 33% in positive margins, defined as tumour 
cells directly at the inked edge of the surgical specimen, compared with rates of 2-10% with tumour-
free pathologic margins [17-19]. The definition of a negative margin has varied substantially in the 
literature. In an attempt to clarify what constitutes a negative margin, most studies report it as the 
absence of invasive or carcinoma in-situ at the inked margin.  
 
Most studies define close margins as ≤ 1 mm or ≤ 2 mm with reported recurrence rates of 2 – 11% 
and 6 – 33% respectively [19,20]. In a survey conducted by Vallasiadou et al in the United Kingdom 
and USA, approximately 50% of surgeons aim for a margin of more than 2 mm, whereas 50% of 
surgeons are happy with a margin of 2 mm or less [21]. A systematic review by Singletary reported 
that some of the lowest rates of local recurrence were in centres that had used narrow margins of 
excision (1 or 2 mm) [22].  
 
Perhaps the important question to address with regards to the margin status is, does increasing the 
size of resection decrease recurrence? In order to answer this question, the optimal extent for 
resection before radiation needs to be defined. Unfortunately there is no consensus on what 
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constitutes an adequate margin of excision for BCT in the reviewed literature. According to Vicini 
et al after analysing the relation of recurrence to the volume resected in 507 patients who had BCT 
between 1968 and 1982, patients with extensive intraductal component tumours who had the largest 
volume resections (defined as specimen volume more than 74 cm3), were correlated to significantly 
lower risk of recurrence in the ipsilateral breast than the patients who had smallest volume 
resections (less than 13 cm3) both for T1 and T2 tumours. For patients with absent extensive 
intraductal component tumours, recurrence rates were significantly lower than for extensive 
intraductal component positive tumours and were not influenced to the same degree by the volume 
of resection thus advocating that the extend of any in-situ carcinoma present to be the determinant of 
the extend of resection [23].  
 
Moreover, the volume of the wide local excision specimen and extent of surgery affect the cosmetic 
outcome. A poor cosmetic result may negatively affect the quality of life. According to Olivotto et 
al, the resection of 70 cm3 or more of breast tissue was more common among the patients that 
reported worse cosmetic outcome compared to those with good outcome (p value 0.03) [24]. This size 
should not be set as the limit because the volume of resected tissue depends on factors such as, the 
tumour size in relation to the breast and the patient’s perception of a good outcome. 
 
In contrast, in a meta-analysis by Housami et al, although positive and close margins significantly 
increase the odds of local recurrence (odds ration 2.02, P value < 0.001), the distance used to declare 
negative margins did not independently contribute to the risk of local recurrence (P value = 0.27) [5]. 
The evidence was weak to suggest that the odds of local recurrence decreased as the threshold 
distance for negative margins increase. In other words, there was no statistically significant 
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improvement in local control in using a wider threshold for negative margin relative to a narrower 
distance [5]. This meta-analysis concluded that a 1 mm margin is sufficient. Increasing the size of 
resection volume will inevitably impact on the cosmetic outcome of BCT. 
 
There is a need to develop a reproducible and reliable technique to address the inherent problem of 
defining margins. Such inherent problems arise because the breast specimens are fatty and the cut 
specimen surface is irregular therefore making surface markings with ink difficult. Routine 
sectioning of specimens does not usually permit examination of the entire surface of the specimen 
and DCIS associated with the tumour may be non-continuous with the tumour [23]. 
 
2. Extent of Margin Involvement 
 
The extend of margin involvement has been identified as a predictor for who would benefit from 
repeat excision of the biopsy site. DiBiase reported the specific number of margins involved by the 
tumour influenced the overall outcome. The 10-year local control rate for women with 1 positive 
surgical margin was 74%, compared with 63% with ≥ 2 positive margins. Furthermore, positive 
margins also significantly affected disease-free survival, with 10-year disease-free survival rates of 
71% and 82% with positive and negative margins, respectively (P = 0.001) [19].  
 
3. Interaction of Margins Status and Other Factors 
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The increased hazard of local recurrence associated with close or positive margin status is even 
more pronounced when additional risk factors such as delayed radiation, presence of extensive 
intraductal component (see below), lack of systemic therapy, or young age are present [20,25-27]. 
 
4. Extensive Intraductal Component (EIC) 
 
EIC is defined as intraductal carcinoma composing > 25% of the tumour mass and extending into 
surrounding normal breast parenchyma, or predominantly intraductal carcinoma with areas of 
microinvasion [26]. Local recurrence rates after BCT range from 2% to 9% for EIC-negative tumours 
and from approximately 10 – 30% for EIC-positive tumours [26]. 
 
 
Clinical Features 
 
1. Age 
 
Studies have reported an increased risk of local recurrence in younger women undergoing BCT for 
invasive and carcinoma in-situ breast cancer. According to Boyages et al, patients with very young 
age, defined as 34 years or younger in their study had higher local recurrence compared to older 
patients (25% vs. 11%, p value 0.001) [28]. The corresponding 5-year actuarial rates of breast cancer 
recurrence were 21% and 9% (p value 0.005) [28]. According to Vicini et al, on a multivariate 
11 
analysis, young age, defined as less than 45 years of age, was independently associated with 
recurrence of the index lesion in patients treated with BCT for DCIS [23]. The 10-year rate of 
ipsilateral failure was 26.1% in younger patients versus 8.6% in older patients (p value 0.03) [23].  
 
Several hypotheses to explain the increased risk in younger women have been postulated based on 
histopathology review such as, greater prevalence of EIC, greater prevalence of higher nuclear 
grade, more inherently aggressive biologic behaviour (triple negative tumours) or higher probability 
of residual disease after initial excisional biopsy in younger patients [6]. 
 
2. Family History 
 
Family history of breast cancer has been considered a possible risk factor for BCT failure. This is 
due to genetic predisposition that can increase the likelihood of cancer in the ipsilateral breast. Some 
studies such as Haffty et al reported a significantly higher rate of ipsilateral breast recurrence at 12 
years of follow-up after BCT in 22 patients with BRCA1 or BRCA2 mutations compared with 105 
patients with sporadic breast cancer (49% vs. 21%; P = 0.007) [29]. Other series have not found 
elevated recurrence rates in patients with a family history of breast cancer [30-32]. 
 
Treatment-Related Features 
 
1. Radiation Therapy 
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Excision of the primary tumour alone is inadequate treatment for early breast cancer. By targeting 
residual malignant cells, radiotherapy post wide local excision reduces local recurrence. This was 
clearly shown in the NSABP B-06 trial in which local recurrence was reduced from 39% to 14% 
with postoperative radiotherapy [9]. In the Milan I trial, the addition of whole-breast radiotherapy 
decreases the recurrence rates from 24% to 6% [10]. In the EORTC study, the risk of a local 
recurrence decreased from 7.3% to 4.3% (P < 0.001) with the additional dose of radiation therapy to 
the lumpectomy cavity [11]. The interval between surgery and radiation may be important and there 
are suggestions that the rates of local recurrence increase if radiotherapy is delayed [33]. 
 
2. Systemic Therapy 
 
Prospective studies have proven a decline in local recurrence with the addition of tamoxifen, 
aromatase inhibitors and chemotherapy after BCT in invasive and intraductal breast cancer [34-36].  
 
A meta-analysis of all tamoxifen trials shows that women with ER-positive tumours significantly 
benefit from 5 years of tamoxifen in reducing the likelihood of recurrence and death, whereas 
women with ER-negative tumours do not [37]. However, in the absence of radiotherapy, aromatase 
inhibitors, tamoxifen or chemotherapy alone do not produce satisfactory rates of local control apart 
from in low-grade, node-negative cancers [38].  
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The management of the unsatisfactory margin in BCT 
 
The goal of BCT is to adequately remove the disease with preservation of satisfactory cosmesis. The 
presence of microscopically clear surgical margin is the most important indicator in ensuring the 
completeness of a surgical excision [39]. On the other hand as mentioned above, a positive margin is 
a major predictor of local recurrence and it generally leads to further resource utilization, patient 
anxiety and leads to the delay in postoperative radiation therapy.  
 
When an unsatisfactory margin is attained after the primary wide local excision, a second procedure 
is usually required in the form of either a re-excision or mastectomy depending on the patient’s 
fitness for surgery or which margin is involved in order to clear the breast of tumour [40].  
 
A number of factors have been correlated with positive margins. Of particular interest are the 
technical ones influenced by a surgeon. The NSABP has developed recommendations for BCT that 
include preoperative diagnosis by needle aspiration biopsy, surgeon orientation of the specimen with 
marking sutures, and intraoperative gross pathologic evaluation of tumour margins [41]. In one study, 
such recommendations resulted in achieving clear margins in 73% of patients compared with 17% 
when a more traditional excisional biopsy was done [42].  
 
Positive margins are significantly associated with large tumour size and the presence of 
lymphovascular invasion and EIC [22, 43]. Others have demonstrated that lobular histology, higher 
grade, and positive axillary nodes are associated with positive margins [40]. 
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A number of studies have evaluated the use of cavity shavings and bed biopsies, but few have 
compared these with standard assessment of margins [33]. A minority of surgeons continue to take 
cavity shavings and bed biopsies routinely for frozen sections in an attempt to clear resection 
margins. Neither has been shown to be reliable indicators of local recurrence. A major concern of 
taking cavity shavings routinely is that significant amounts of extra breast tissue can be removed 
resulting in poor cosmetic outcome. Centres that do not use these method report excellent local 
control rates [5, 22]. If any role at all, bed biopsies or cavity shavings are only of value and warranted 
where there is a concern at operation that one particular margin is involved and should not be done 
routinely.  
 
Re-excision of positive or close margins is done on the premise that a second procedure (i.e. re-
excision or mastectomy) will completely excise the cancer with resulting negative margins and 
hence reduce local recurrence. Local re-excision rate alone ranges between 24% and 57% [44-46]. 
Smitt et al [47] have shown that re-excision of inadequate margins can achieve local control rates 
similar to those achieved when the initial excision has been adequate. However, whether in fact re-
excision helps to decrease local recurrence remains an unanswered question [48]. Few small studies 
that have studied re-excision of positive margins or have assessed local recurrence after re-excision 
compared to no further surgery have not shown a significant difference in local recurrence rate over 
a short follow-up period [45,49-53].  The study by Wiley et al suggested that the host response to injury 
might destroy residual infiltrating ductal cancer in some instances in which the tumour was 
incompletely resected [49]. Solin et al have suggested that, in some instances, close or focally 
positive margins can be compensated for by adjuvant radiotherapy [53]. Surgeons have to balance the 
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extent of surgical margin clearance and against cosmetic outcome. Most surgeons are unwilling to 
sacrifice the former for the latter, which would leave the responsibility for local control with the 
radiotherapist [40]. Furthermore, it has been shown that, with proper selection criteria, it may be safe 
to omit adjuvant radiotherapy in patients with adequate margins for example in DCIS [54,55].  
 
In numerous reported series, residual cancer is detected in approximately 50% of re-excisions after 
partial mastectomy or lumpectomy with positive margins [22,50,56,57]. In other studies, residual cancer 
following re-excision for close but clear margins has been noted to be in the range of 22% to 43% 
[57-59]. 
 
In one of the large randomized controlled trials on BCT by Fisher et al, lumpectomy-treated women 
whose resected specimen margins were found on histologic examination to contain tumour 
underwent total mastectomy rather then re-excision [9].  
Therefore the management of unsatisfactory margin post primary WLE depends on patient factors, 
surgeon factors and institutional guidelines. 
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Five-year review of breast-conserving therapy for breast carcinoma (BCT): surgical margins, 
re-excision and local recurrence in a single tertiary centre 
 
*P. M. Nashidengo, †E. Panieri, ‡L. Cairncross 
 
Abstract 
 
Background: BCT is the wide local excision of the tumour usually followed by radiation treatment 
to the breast. It is the mainstay treatment for carefully selected patients with early breast cancer. 
There has not been a formal audit to review the outcomes of BCT in our unit.  
Objectives: To determine the excision margins, re-excision and local recurrence rates.     
Methods: A histopathological and oncology records review of BCT patients from 1st January 2006 
to 31st December 2010. The health faculty’s ethics committee granted approval. Data points accrued 
included age, pathological tumour size and nodal status, tumour histology, oestrogen receptor status, 
presence of lymphovascular invasion, volume of specimen excised, margin status, management of 
involved or close margins, radiotherapy, ipsilateral breast recurrence rate and duration of follow up.   
Results: A total of 192 patients had BCT. The mean age is 53 years. A median of 229.5 cm3 volume 
of specimen was excised. Infiltrating ductal carcinoma was the commonest histological type at 
79.1%. The resection margin status: positive margins rate of 15.1%, 8.3 % close margin (≤ 1 mm), 
35.9% 1 – 5 mm, 23.4% 6 – 10 mm and > 10 mm 17.2%. An overall of 27 (14.0%) patients 
underwent a second procedure. 16 (8.3%) had re-excision and 10 (5.2%) had a mastectomy. At a 
median follow up of 60 months, a total of 11 (6.8%) patients had recurrence. Median time to 
recurrence is 39 month.  
Conclusion: Positive and close margin re-excision and local recurrence rates in our unit are 
acceptable and comparable to other units in South Africa and internationally.  
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Introduction 
 
Breast cancer affects 1 million women in the developed world every year [1]. The burden of breast 
cancer is also on the rise in the developing world. According to Jones [2], it is estimated that 70% of 
new cancer cases will occur in the developing world by the year 2020. 
 
Until the 1970s, the Halsted radical mastectomy had been the surgical procedure in the management 
of breast cancer irrespective of size. It was described and performed by William Stewart Halsted in 
1882 [3]. It included the excision of the skin, the breast and underlying pectoralis muscles. Patients 
also underwent an axillary lymph node dissection. A skin graft was often used to close the wound 
defect.  Patients were left with morbid disfiguring appearances.  
 
Modified radical mastectomy was shown to be as effectual as radical mastectomy and less 
mutilating. Modified radical mastectomy remains to be applicable to certain patients. However, BCT 
has become the adopted procedure for the surgical management of early breast cancer. BCT refers to 
the surgical excision of the primary breast cancer tumour with a rim of normal breast tissue, 
followed by radiation therapy. It is also referred to in the literature as lumpectomy, partial 
mastectomy or segmental mastectomy [4]. 
 
Over the past forty years prospective large multicentre randomized controlled trials (RCTs) in 
Europe and United States have provided level 1 evidence that there is no statistically significant 
difference in the overall long-term survival between mastectomy and BCT in appropriately selected 
patients treated for early breast cancer [5]. Although the overall long-term survival is similar between 
the two procedures, patients undergoing BCT are at a recognized risk of ipsilateral breast tumour 
recurrence [6]. The success rate of BCT relies upon appropriate patient selection, surgical technique, 
and postoperative radiotherapy to eliminate microscopic tumour cells in the ipsilateral breast. The 
goals of BCT are therefore to resect the tumour with clear microscopic margins and to achieve 
acceptable cosmetic outcomes without compromising patient survival.  
 
BCT has become the standard of care in our oncology and endocrine surgical unit for patients 
meeting the above criteria diagnosed with early breast cancer at Groote Schuur Hospital. There has 
not been a formal audit to review the outcomes of BCT in the unit. In South Africa, there has been 
only one retrospective study on BCT. In 2005, Mannell, a part-time staff member at the University 
of Witwatersrand, published a retrospective review of 165 patients that underwent BCT at her 
private practice at Linksfield and Parklane Clinics over a period of 12 years. In her series 7 out of 
165 patients had re-excision and recurrence rate of 5.5%[7]. 
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Materials and Methods  
 
This is a 5 years review of a series of consecutive patients who underwent BCT in a specialized unit 
at Groote Schuur Hospital from the 1st January 2006 until the 31st December 2010. It is based on 
histo-pathology and oncology records. Approval for the study was obtained from the University of 
Cape Town’s Faculty of Health Sciences Human Research Ethics Committee. Inclusion criteria are 
all the histologically confirmed invasive or in situ breast carcinoma patients. Exclusion criteria are 
the patients with benign pathological diagnoses, incomplete histo-pathological reports, patient with 
missing folder numbers, patients’ whose folders could not be found at records and patients lost to 
follow up during the study period. Primary endpoints were margin status, rate and type of re-
operation and recurrence rate. Secondary outcomes are to identify factors associated with margin 
status, re-excision and recurrence. Data was retrieved from the unit’s prospectively collected patient 
surgical breast cancer Microsoft Access 2010 database by identifying all the patients that had wide 
local excisions (WLEs). Additional data was retrieved from patients’ folders, National Health 
Laboratory Service (NHLS) pathology reports and the radiation oncology records.   
 
Data from identified patients was captured using an online password-protected forms designed with 
Google Forms and subsequently transferred onto a spreadsheet. Limiting access and using proxy 
patient identifiers maintained patient confidentiality.  
 
The following variables captured: age, pathological tumour size (pT), pathological node status (pN), 
tumour grade (low, intermediate or high), histological type of tumour, volume of resected specimen 
in cm3, oestrogen receptor (ER) status, presence of lymphovascular invasion, margin status, type of 
tumour at margin, management of positive margins (re-excision vs. mastectomy), type of residual 
tumour in the resection or mastectomy specimen), radiation therapy post WLE – if completed or not, 
local recurrence and time to recurrence, type of tumour and management of recurrence, duration of 
follow up at oncology outpatients’ department. Extensive intraductal component was not recorded as 
it did not feature in the NHLS pathology reports. 
Positive margin is interpreted as the presence of breast cancer, invasive and/or non-invasive at the 
inked surgical margin. The absence of tumour within a specified distance of more than 1 mm or 2 
mm from the resection margin was regarded as a negative margin. A close margin is the presence of 
tumour within that distance (1 mm) but not at the resection margin. Volume of specimen is the gross 
volume of excised cancer with surrounding breast tissue calculated by multiplying height by width 
by length using the dimensions as described in the pathology report.  
 
The wide local excision procedure in the unit is performed as per standards for BCT [4]. An elliptical 
skin incision followed by excision of the tumour together with circumferential normal breast tissue 
of 1 cm to ensure that the resected specimen margins are free of the tumour with tactile perception. 
The axilla was managed as indicated by clinical or sentinel lymph node biopsy. Lymph node 
clearance was limited to Level II dissection. Local recurrence refers to the first site histologically 
proven relapse of invasive or intraductal carcinoma post WLE in the ipsilateral breast. 
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Statistical analysis was performed using the IBM SPSS Statistics version 22 for Macintosh software. 
Continuous variables were expressed as means and median as measures of central tendencies and 
categorical variables as frequencies and percentages. The Chi-Square test was used to determine the 
associations between categorical data variables to recurrence. 
 
 
Results 
 
Patients and disease characteristics (Table 1) 
 
The query design for the unit’s Microsoft Access database retrieved 242 patients that had procedures 
recorded as WLEs. Fifty patients were excluded from the study for the following reasons: lost to 
follow up (31), incomplete histo-pathology report (8), benign pathology (3) (benign phylloides 2 and 
juvenile fibroadenoma 1), diagnostic radio guided occult lesion localization (2), incomplete database 
entry (3) (no name and folder number) and unable to retrieve pathology or oncology records (3).  
Therefore a total of 192 patients underwent BCT in the surgical oncology unit within the period of 
1st of January 2006 to 31st December 2010 as per inclusion criteria. The patients’ age ranged from 
25 years to 84 years with a mean age of 53.4 years. More than half of the patients (54.7%) were 
above 51 years. 5.2% of patients were young women who were less than 35 years. The majority of 
patients (91.7%) had breast cancers with a maximal diameter of 5 cm. A total of 5 and 4 patients had 
tumours categorized as T3 and T4 by pathology respectively. Seven patients had WLE post 
neoadjuvant chemotherapy. 
115 patients (59.9%) had no pathological nodal involvement (pN0) and 61 (29.8%) had involved 
nodes (pN1 to pN3). 16 patients (8.3%) had unknown pathological nodal status (pNx). Low grade 
cancer was present in 62 patients (32.3%), intermediate grade in 77 patients (40.1%) and high grade 
in 53 patients (27.6%). 145 patients (75.5%) had absence of lymphovascular invasion and 47 
patients (24.5%) had presence of lymphovascular invasion. 
Two-thirds of patients had oestrogen receptor (ER) positive cancers (67.7%), 14.1% had negative 
oestrogen receptors. ER receptor status was not recorded in 35 patients (18.2%) in the 
histopathology reports. 
 
The commonest histological tumour type was infiltrative ductal carcinoma (IDC) at 79.1%. It was 
associated with DCIS in 40.6%. Infiltrative lobular carcinoma (ILC) was present in 5.3% followed 
by DCIS in 3.6% of the patients.  
The median volume of the specimens was 229.50 cm3 with a range of 4 cm3 to 10 530 cm3.  
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Table 1. Patient and tumour characteristics 
Variable Number of patients (frequency) Percentage (%) 
Age Category (in years): 
 ≤ 35 
 36 – 50 
 ≥ 51 
 
 
10 
77 
105 
 
5.2 
40.1 
54.7 
Pathological Tumour Size: 
 Tis 
 T1 
 T2 
 T3 
 T4 
 
7 
82 
94 
5 
4 
 
 
3.6 
42.7 
49.0 
2.6 
2.1 
Pathological Lymph Node Status: 
 Nx 
 N0 
 N1 
 N2 
 N3 
 
16 
115 
47 
9 
5 
 
 
8.3 
59.9 
24.5 
2.7 
2.6 
 
 
Tumour Grade: 
 Low 
 Intermediate 
 High 
 
62 
77 
53 
 
 
32.3 
40.1 
27.6 
Lymphovascular Invasion: 
 No Lymphovascular Invasion 
 Lymphovascular Invasion 
 
ER Receptor Status: 
 ER Positive 
 ER Negative 
 Unknown 
 
 
145 
47 
 
 
130 
27 
35 
 
75.5 
24.5 
 
 
67.7 
14.1 
18.2 
 
Excision Margins (mm): 
 Positive 
 Close (≤ 1) 
 1 – 5  
 6 – 10 
 > 10 
 
29 
16 
69 
45 
33 
 
 
15.1 
8.3 
35.9 
23.4 
17.2 
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Margin status and management 
 
Of the 192 women who were treated with BCT, 29 had an involved or positive margin after the 
initial excision (15.1%). The commonest pathology at the involved margin was carcinoma in-situ at 
(15 patients) 51.7%. Sixteen patients (8.3%) had a close margin of less than 1 mm. Sixty-nine 
patients (35.9%) had a margin between 1 mm to 5 mm. Seventy-eight patients (40.6%) had a margin 
of more than 6 mm (Figure 1). Of the patients that had carcinoma in-situ at the margins, 8 had 
repeated WLE, one had a mastectomy and 6 had no further surgical intervention. In the infiltrative 
carcinoma group (14 patients), 6 had a repeated WLE, 2 had mastectomy and 6 had no further 
surgical intervention (Table 2).   
 
A total of ten patients had no further surgery for involved margins, six and four in the DCIS and 
infiltrative carcinoma groups respectively. The reasons for no further surgery in the DICS group 
were, one patient developed severe pancreatitis and lost to follow up, 4 patients had involved deep 
margins and one transferred to another province. In the infiltrative carcinoma group, one was 
deemed surgical unfit due to advanced age, 2 had tumour at deep margins infiltrating the major 
pectoralis muscle and we could not determine the reason in the records for one patient. 
 
For the women that had a close margin (<1 mm), 5 and 11 patients had DCIS and infiltrative 
carcinoma respectively. In the DCIS group 3 patients had a subsequent mastectomy and one patient 
each had a repeat WLE and no further surgery due to deep close margins. In the infiltrative close 
margin group, no patient had a repeat WLE, 2 had mastectomy and 9 had no further surgery mostly 
due to deep close margins.  
 
In the group of women who had excision margin 1 to 5 mm, one (6.3%) had a re-excision for 
infiltrative carcinoma and none had a mastectomy. Neither re-excision nor mastectomy was 
performed in the women with excision margins of more than 6 mm.  
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Figure 1. Bar chart showing the percentages of the excision margins 
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Table 2. Summary of management of positive and close margins after initial wide local excision 
according to histo-pathology 
 Positive Margin  Close Margin 
DCIS Infiltrative 
Carcinoma 
 
 
DCIS Infiltrative  
Carcinoma 
Management 
of Margin 
Re-WLE  8 6  1 0 
Mastectomy  1 4  3 2 
No Surgery   6 4  1 9 
 
A total of twenty-six patients had subsequent repeat WLE or mastectomy for involved (19), close 
(6) and 1-5 mm (1) margins, giving an overall re-excision rate of 13.5%. Re-excision rate according 
to margin status is 9.9% for positive and 3.1% for close margins. The rate was similar for DCIS and 
invasive carcinoma in positive margin group.  
 
 A total of ten patients had mastectomy for involved or close margins giving an overall mastectomy 
rate to 5.2% for this study (Table 2).  
 
Residual tumour rate in the re-excision and mastectomy was 50.0% and 63.6% respectively. The 
most common residual histology in both groups was DCIS. One patient that had involved margins in 
the re-excision specimen had a subsequent mastectomy for persistent margin involved. The 
histology in this patient was IDC in association with DCIS.  
 
The most significant predictors for re-excision were a positive margin (p value 0.000) and the 
pathological tumour size (p value 0.009). The following did not predict re-excision: age (p value 
0.825), volume of the primary resected specimen (p value 0.148), tumour histological grade (p value 
0.434), tumour oestrogen receptor status (p value 0.786) and lymphovascular invasion (p value 
0.77). 
 
 
Recurrence  
 
Local recurrence (LR) is hereby defined as the first recurrence of a tumour in the chest wall or in the 
operative scar in the ipsilateral breast after the initial WLE. During the median follow-up period of 
60 months, a total of eleven patients had histologically confirmed recurrence. A total of 31 patients 
lost to follow during the observational period, giving the relative observed rate of local recurrence of 
6.8%. The median time to recurrence was 39 months. All the cases of recurrences were confirmed 
by histology. Infiltrative ductal carcinoma was the most common histological type of breast cancer 
at 63.6% followed by DCIS at 18.2%.  
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LR was 6.9% in patients with histologically positive margins, 5.8% in patients with 1 -5 mm 
margins, 6.7% in patients with 6 – 10 mm margins, 6.1% in patients with > 10 mm margins. No 
recurrence was noted in the close margin group. There was no statistical difference between the 
resection margins (Pearson Chi-square 0.890). 
  
The total follow up duration period was calculated from the date of diagnosis to the discharge date 
or the date the patient was last seen at the oncology clinic at the time of data collection.  
Cross tabulation analysis of the rest of variables such as the age of the patient, tumour pathological 
size, tumour grade, oestrogen receptor status, presence of lymphovascular invasion, completion of 
radiotherapy post breast conserving surgery, did not show a correlation with local recurrence (Table 
3). 
Table 3. Effect of different variables on local recurrence 
 
Age (years): 
     </= 35 
     35 – 50 
     >/= 51 
Pearson Chi-square statistic 
0.436 
Pathological T Stage: 
    Tis 
     T1 
     T2 
     T3 
     T4 
0.684 
Tumour Grade: 
     Low 
     Intermediate 
     High 
 
0.347 
Receptor Status: 
     ER Positive 
     ER Negative 
     ER Unknown 
 
0.173 
Lymphovascular Invasion: 
     LVI 
     No LVI 
 
0.617 
Radiotherapy Completion: 
     Completed 
     Not Completed 
 
0.960 
Margin: 
     Positive 
     < 1 mm 
     1 – 5 mm 
     6 – 10 mm 
     > 10 mm 
 
0.890 
 
 
 
Radiation treatment 
 
A total of 157 patients (81.8%) were referred to the radiation oncology unit for radiotherapy post 
surgery, of which 152 (96.8%) completed the radiotherapy course. 
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Discussion 
 
This study was conducted to review breast-conserving therapy for breast carcinoma in a single 
tertiary centre. It is the largest study to date conducted in South Africa. The rate of margin positivity 
was 15.1%. This rate is comparable to and lower than international studies that vary widely from 3% 
to 52% [7-17] (Table 4). The wide range in margin positive margin rates internationally is due to a 
number of factors. These include: inconsistent definitions of a positive margin, differences in the use 
of intraoperative pathological assessment of margins, variations in the handling of surgical 
specimens and in pathological sampling of margins. The type of surgery also affected these 
numbers, specifically whether surgery was diagnostic or therapeutic in intent. Also, different studies 
had a wide range of actual number of surgical resections that were performed to generate the 
published positive margin rates [18].  
 
Table 4. Studies on positive margins and local recurrence by margin status 
 Local Recurrence by Margin 
Status (%) 
 
 
 
Author(s) 
Number 
of Patients 
Positive 
Margins 
(%) 
 
 
Negative 
 
 
Positive 
 
 
Follow-Up 
Mannell [7] 165 6  5.5* 65 months median 
Veronesi et al (Milan I) 
[8] 
1973  9 17 6.5-year median 
Van Dongen et al 
(EORTC) [9] 
431  9 20 8-year actuarial 
DiBiase et al [10] 453 19 13 33 120 months 
Peterson et al [11] 120 16 8 10 5-year actuarial 
Leborgne et al [12] 817 6 9 6 9-year actuarial 
Cowen et al [13] 152 48.3a 
51.7b 
- 14a 
31* 
5-year crude 
Dewar et al [14] 663 19.9 6 14 10-year actuarial 
Kini et al [15] 400 8 6 17 10-year actuarial 
Mansfield et al [16] 704 15 8 16 120 months 
Pierce et al [17] 396 3 3 10 5-year actuarial 
Nashidengo (current 
study) 
192 15.1  6.1c 
5.7d 
60 months median 
Key:  a = Focally positive margin 
 b = Extensively (Multiple) positive margin 
 c = Positive margin 
 d = Overall  
 
 
In the current study, patients who had tumours with lymphovascular invasion were more likely to 
have a positive margin (Pearson Chi-square 0.002). Singletary reported that positive margin was 
significantly associated with large tumour size, young age, axillary node positive status, presence of 
lymphovascular invasion, and an extensive intraductal component [19]. Aziz et al reported that 
patients who were younger or had tumours with lymphovascular invasion or a DCIS component 
were more likely to have a positive margin on a univariate analysis [20]. In the current study, the 
following variables did not predict positive margins: age, pathological tumour size, pathological 
axillary nodal status, histological diagnosis, grade and oestrogen receptor status. 
33 
 
Nearly all the tumours in our study are pT1 and pT2 sized (91.7%). This is in keeping with 
international standards and guidelines for BCT for early breast cancer. However, the current trend 
internationally is that the eligibility of BCT has been expanded to locally advanced breast cancers 
post neoadjuvant chemotherapy. Primary tumour response rates of approximately 80% have been 
observed post neoadjuvant [21]. Several RCTs have demonstrated the oncologic safety of 
neoadjuvant chemotherapy locally advanced breast cancer. The NSABP B-18 trial demonstrated that 
there was no statistically significant difference in the local recurrence rate following BCT in the 
preoperative and postoperative chemotherapy arms [22].  
 
This practice is not yet adopted in our surgical oncology unit. Although a total of six patients had 
WLE post neoadjuvant chemotherapy, we postulate that these patients either had large breast to 
tumour ratio or their tumours were located high on the chest wall or in the inframamary fold that 
would have rendered a mastectomy difficult. 
 
Positive resection margins have been associated with a higher local recurrence rate [5,10,19,23,24]. It is a 
standard practice in our unit to re-excise a positive margin with the intent of achieving clear margin 
prior to radiation therapy. The decision for re-excision is discussed in a multi-disciplinary team 
comprising of surgeons with special interests in breast cancer, medical and radiation oncologists, 
histopathologists and radiologists. A variety of factors are taken into consideration before 
proceeding with re-excision, such as, patient age, co-morbidities, life expectancy, extent of excision, 
extent of margin involvement, tumour characteristics, and whether the patient will receive adjuvant 
treatment. Involved or close margins deep down to fascia are not re-excised due to the morbidity 
that results from partial muscle excision on the chest wall. Such patients usually receive boost 
radiation doses.  
 
Our unit’s overall re-excision rate of 13.5% is lower than most international studies. An 
observational study of 2206 women reported an overall re-excision rate of 22.9 %. It is notable that 
within this study, there were wide substantial variations between surgeons and institutions following 
BCT [25]. The most consistent and reliable risk factors for re-excision appear to be the presence of 
micro-calcifications, EIC or DCIS, and lobular histological type [26]. A palpable tumour is more 
likely to facilitate complete excision while the existence of insensible DCIS outside the sensible part 
of the tumour can result in involved resection margin and the subsequent need for a second 
procedure.  
 
Globally, indications for re-excision for involved or close margins are under constant review. A 
meta-analysis that included 33 studies and 28 162 patients with ipsilateral recurrences supports the 
use of no ink on the tumour as an adequate negative margin of resection for invasive breast cancer. 
The authors concluded that there was no evidence that a wider margin of normal breast tissue than 
no ink on the tumour decreased the rate of recurrence in the clinical setting of multimodality 
treatment [27]. Re-excision is therefore not mandatory for close margins < 1mm and each case should 
be individualised.  
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In our study, the mastectomy rate post the initial WLE for positive margin is 0.5% and 2.1% for 
DCIS and invasive cancer respectively. For close margins, it is 1.6% and 1.0% for DCIS and 
invasive cancer respectively. The surgical decision to a re-excision versus a mastectomy is made at a 
combined breast clinic. Tumour factors and patient preferences are taken into consideration. Patients 
with diffuse rather than focally involved margins are offered a mastectomy. A mastectomy is the 
preferred surgical treatment for multicentric DCIS or persistent positive margin after repeated WLE.  
 
The residual tumour rate in re-excisions and mastectomy groups is 50% and 63.6% respectively. 
These rates are comparable to international studies [19,28,29]. In our study, the final margin status 
measurements were not captured and therefore we are not able to report the final close margin rate. 
However we noted one patient (0.52%) who had undergone more than one surgical procedure, a re-
excision followed by a mastectomy for persistent positive margin.  
 
The median volume of the excised specimen is 229.5 cm3 in our study. This seems to be larger than 
the sizes of 60 cm3 and 70 cm3 quoted by Vicini et al [30] and Olivotto et al [31]. The volume of 
resected breast tissue has a direct impact on cosmesis in breast conserving surgery. According to 
Olivotto et al, tumours greater than 70 cm3 resulted in a significant increase in the number of 
cosmetic failures [31]. We postulate that the larger volume reflects the likelihood that our patients 
presented with slightly larger sized-tumours and larger breasts. The cosmetic effects of BCT were 
not part of the current study. A different study in our unit looking into this aspect will provide more 
insight. 
 
Our study shows a relative observed recurrence of 6.8% at a median follow-up of 60 months. The 
recurrence rate in the involved or positive margin patient group is 6.8%. Our local recurrence rate is 
comparable, if not lower, to international studies that show a local recurrence that varies between 
2% to 13% for negative margins and 5.5% to 33% for positive margins [7,9-17,23,24] (Table 4). Our 
data was not sufficient to demonstrate any statistically significant difference between local 
recurrence and the variables studied.  
 
A total of 156 (81.3%) of the 192 patients that had WLE were referred for radiotherapy. It is 
standard that patients over the age of 80 years of age or with significant comorbidities are not 
referred for radiation therapy. There were patients that lost to follow-up after their surgery due to 
defaulting, some followed up with private radiation oncologists, and some moved to other 
provinces, some declined further treatment. Of the referred patients, 151 (96.8%) completed 
radiation treatment.  
 
Our study has a number of limitations. First, this was a retrospective study based on the local 
hospital sample. The database may not have included all the patients that had WLE and incomplete 
histological reports. We could not access information on non-retrieved folders. This lack of records 
may have influenced the final outcomes of the study and it reflects the general challenges public 
health sector with regards to poor record keeping. Therefore the analysis is subject to selection bias. 
The recurrence rate was calculated taking into consideration the patients that are lost to follow up 
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during the observational period.  
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Conclusion 
 
Our study reviews the outcomes of BCT women with early breast cancer in a single tertiary centre. 
It represents the largest cohort of patients managed at a single institution in South Africa. Apart 
from the inherent limitation to this retrospective review, the median follow up period of 60 months 
is reasonable and provides valuable information regarding our unit’s surgical margins in BCT, re-
excision and ipsilateral breast tumour recurrence rate. The analysis of 192 patients demonstrates 
outcomes that appear well in keeping with those reported in the international literature in what 
regards the local recurrence rate. 
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Appendix A: Data Capture Form 
  
40 
 
41 
  
42 
 
43 
  
44 
  
45 
 
If Recurrence, Time To Recurrence * 
(Months) 
Your answer 
Surgery For Local Recurrence? * 
0 Yes 
0 No 
0 Not Applicable 
0 Not Specified 
Management of Local Recurrence * 
D Mastectomy 
D Hormonal Treatment 
D Radiation 
D Chemotherapy 
D Not Specified 
D Not Applicable 
Chemotherapy * 
0 Complete 
0 Not Complete 
0 Not Specified 
0 Not Applicable 
Page 1 of 1 
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Appendix B: American Joint Committee on Cancer Staging for Breast Cancer 
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American Joint Committee on Cancer 
Breast Cancer Staging ~ ,,,h EDITION 
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
TO No evidence of primary tumor 
Tis Carcinoma in situ 
TIS (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget's) Paget', disease of the nipple NOT associated with 
invasive carcinoma and/or carcinoma in situ (DCIS 
and/or LOS) in the underlying breast parendlyma. 
Carcinomas in the breast parenchyma associated 
with Paget's disease are categorized based on the 
sizeand charactenstics of the parenchymal disease, 
although the presen<e of Paget's disease should still 
be noted 
' T3 \ ••• , •• _....... >SO mm 
TI Tumors; 20 mm in greatest dimension 
Tlml Tumors; 1 mm in greatest dimension 
T1a Tumor> 1 mm but ~ S mm in greatest dimension 
Tlb Tumor> 5 mm but :S 10 nvn in greatest dimension 
Tlc Tumor> 10 mm but :s: 20 mm in greatest dimension 
n Tumor> 20 rrvn buts; 50 mm in greatest dimension 
n Tumor> SO mm in greatest dimension 
ANATOMIC STAGE/PROGNOSTIC GROUPS 
Distant Metastases (M) 
MO No dinical orradiographic evidence of distant 
metastases 
cMO(l+) No clinical or radiographic evidence of distant 
metastases, but deposits of molecularly or 
microsa>pically dete<ted tumor cells in circulating 
blood, bone marrow, or other nonregional nodal 
tissue that are no larger than 0.2 mm in a p.atient 
without symptoms or signs of metastases 
Ml Distant detectable metastases as detennined by 
classic clinical and radiographic means and/or 
histologically proven larger than 0.2 mm 
Stage o TIS 
Stage IA T1* 
Stage lB TO 
T1* 
Stage HA TO 
n· 
T2 
Stage IIB T2 
T3 
Stage IIIA TO 
n • 
T2 
T3 
T3 
Stage IIIB T4 
T4 
T4 
Stage IIIC AnyT 
Stage IV Any T 
• 
-
Financial support for AJCC 7th Edit ion Staging Post ers 
provid ed by t he American Cancer Society 
NO MO 
NO MO 
N1mi MO 
N1mi MO 
N1 .. MO 
N1** MO 
NO MO 
N1 MO 
NO MO 
N2 MO 
N2 MO 
N2 MO 
N1 MO 
N2 MO 
NO MO 
N1 MO 
N2 MO 
N3 MO 
Any N M1 
T4a Direct extension 
\ 
to chest wa ll 
not including 
pectoralis muscle. 
\ 
T4 Tumor of any size with direct extension to the di est 
wall and/or to the skin (ulceration or skin nodules) 
Note: Invasion of the dermis alone does not qualify 
as T4 
T4a Extension to the diest wall not including only 
pectoralis muscle adherence/invasion 
T4b Ulceration and/or ipsilateral satemte nodules and/or 
edema (including peau d'orange) of the skin, which 
do not meet the criteria for infl.ammatOl'y carcinoma 
T4< Both T4a and T4b 
T4d Inflammatory carcinoma (see "RIJles for 
Classification") 
Notes 
• T1 includesllmi. 
H TO and Tl tumors with nodal micrometastase5 only 
are excluded from Stage IIA and are cla5sified Stage 
18. 
• MOincludesMO(i+). 
• ThedesignationpJ.ltlisnotvalid;anyMOshouldbe 
dinkal 
• If a patient presents with Ml prioftoneoadpYant 
systemictherapy,thestage~conside-redStage 
IV and remails Stage IV regardless of response to 
neoadjuvanttherapy. 
• Stage dfsignation may be changed if postsurgical 
imagingstudies revealthepresenceofdistant 
metastase5,providedthattlw'studiesarenrried 
out within 4 months of diagnosis N1 the absence of 
diseaseprogressionandpravidedthatthepatient 
has not received neoadjuvanttherapy. 
• Postneoadjuvanttherapyisdesignatedwith·'fC· 
or ·yp· prefix. Of note. no stage group is assigned 
if thefeisa completepathologkresponse (CR)to 
neoadjuvant therapy, for example, ypfOypNOcMO . 
1 of2 
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American Joint Committee on Cancer 
Breast Cancer Staging IIMlllr'hEDITION 
Regional Lymph Nodes (N) 
CLINICAL 
NX Regional lymph nodes cannot be assessed [for example, previou~y removed) 
NO No regional lymph node metastases 
Nl Metastases to movable ipsilateral level I, II axillary lymph node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are dinically fixed or matted; 
or in dinicallydetected' ipsilateral internal mammary nodes in the absence of dinically 
evident axiDary lymph node metastases 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or 
to other structures 
N2b Metastases only in dinically detected' ipsilateral internal mammary nodes and in the 
absence of clinically evident lev~ I, II axillary lymph node metastases 
N3 Metastases in ipsilateral infraclavicular (level Ill axillary) lymph node(~ w~h or without 
level 1.11 axillary lymph node involvement"' in dinically detected' ipsilateral internal 
mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; 
or metastases in ips1ateral supradavicular lymph node(s) w~h or without axilary or 
internal mammary lymph node involvement 
N3a Metastases in ipsilateral infraclavicular lymph node(s) 
N3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s) 
N3c Metastases in ipsilateral supraclavicular lymph node(~ 
Notes 
• "Clinically detected"' is defined as detected by imaging studies (exchlding lymphoscintigraph')') or 
bydinical e1tamination and having characteristics highly suspicious for malignancy or a presumed 
pathologic macrometastasis based on fine nttdlt aspiration biopsy with cytologictxamination. 
Confirmation of clinkally detected metastatk dise:ase by fine needle aspiration without excision 
biopsy is designated with an (f) suffix, for example, cN3a(f). Exi:isional biopsy of a lymph node or 
biopsy of a sentinel node, intheabsenceof assignrneflt of a pT, isdassffiedasaclinical N, for example 
cNl. Information regarding the confirmation of thto nodal status will be designated in site-specific 
factors as dinical, fine needle aspiration, core biopsy, or sentinel lymph node biopsy. Pathologk 
~fic.ation (pN) is used for excision Of sentinel ~mph node biopsy only in conjunction with a 
pathologicTassignment 
pNlmi 
>0.2·2 mm or more 
than 200 cells 
0 
pNl a: 1-3 nodes 
(at least one tumor 
deposit >2.0 mm) 
pNO(i+) -1:. 
~f 
' 
. 
~oi mm or cluster of 
fewer than 200 cells 
pN3a: ~ 1 O nodes 
(at least one tumor 
deposit >2.0 mm) 
pN2a: 4-9 nodes 
(at least one tumor 
~ deposit>~~ 
i) 1 t 
PATHOLOGIC (PN)* 
pNX Regional lymph nodes cannot be assessed (for example, previously removed, or not 
removed for pathologic study) 
pNO No regional lymph node metastasis identified h~tologically 
Note: Isolated tumor ceU dusters 01() are defined as small clusters of cells not 
greater than 01 mm, or single tumorc~ls, or a duster of fewer than 200 cells in 
a single histologic cross-,ection. lTCs may be detected by routine histology or by 
immunohistochemical OH() methods. Nodes containing only ITCs are exduded from the 
total positive node count for purposes of N classifi<ation but should be included in the 
total number of nodes evaluated. 
pNO(H No regional lymph node metastases histologically, negative IHC 
pNO(I+) Mal~na•tcel~in reg~nal lymph node(s) nogreaterthan0.2 mm (detectedbyH&Eor 
IHC including ITC) 
pNO(mol-) No regional lymph node metastases histologically, negative molecu~r finding, (RT-PCR) 
pNO(mol+) Positive molecular findings (RT-PCR)" , but oo reg~nal lymph node metastases 
detected by histology or IHC 
pNl Micrometastases;"' metastases in 1- 3 a~llary lymph node~ and/or in internal 
mammary nodes with metastases detected by sentinel lymph node biopsy but oot 
clinically detected'" 
pNlml Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater 
than2.0 mm) 
pNla Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2.0 mm 
pNlb Metastases in internal mammary nocfe5 with micrometastases or maaometastases 
detected by sentin~ lymph node b~psy but not clinically detected" ' 
pNlc Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes with 
micrometastases or macrornetastases dete<ted by sentinel lymph node biopsy but oot 
clinically detected 
pN2 Metastases in 4- 9 a~llary lymph node~ or in dinically detected''" internal mammary 
lymph nodes in theabsence of axillary lymph node metastases 
pN2a Metastases in 4- 9 a~llary lymph nodes (at least one tumor depos~ greater than 2.0 
mm) 
pN2b Metastases in clinically detected"" internal mammary lymph nodes in the absence of 
axillary l\,mph node metastases 
pN3 Metastases in 10 or more axillary lymph node~ or in infraclavicular Oevel Ill axillary) 
lymph nodes; or in cfinically detected"" ipsilateral internal mammary lymph 
nodes io the presence of one or more positive level 1. 11 axillary lymph nodes; or in 
more than three a~llary lymph nodes and in internal mammary lymph nodes with 
micrometastases or macrornetastases dete<ted by sentinel lymph node biopsy but not 
clinicallydetected"';orin ipsilateral supraclavicular lymph nodes 
pN3a Metastases in 10 or more axillary lymph nodes(at least one tumor depos~ greater thao 
2.0 mm); or metastases to the infradavicular (lev~ Ill axillary lymph) nodes 
pN3b Metastases in clinically detected-· ipsilateral internal mammary lymph nodes 
in the presence of one or more positive axillary lymph nodes; or in more than three 
axiOary l!'ffiph nodes and in internal mammary lymph nodes with micrometastases or 
macrometastases detected by sentin6 lymph node b~psy but not dinkally detected"' g 
pN3c Metastases in ipsilateral supraclavicular 
lymph nodes 
Notes 
• Cl.mific.ation is bawd on axillary lymph node di$section with or without sentinel lymph node 
biopsy. a assification based solety on sentinel lymph node biopsy without subsequent axillary 
lymph node dissection is designated (sn) for ·senti~ node,· for uample. pNO(sn~ 
•• RT -PCR: revme transcriptase/polymerase chain reaction. 
... · Not clinically detected· i$ defined as not detected by imaging studies (excluding 
lymphosdntigraphy) or not detected by din ic.a I examination. 
•"* ·clinic.all)' detectecr is defined as detected by imaging studies (excluding lymphos.ciitigraphy) or 
by clinica I examination and having characteristics highty suspicious for malignancy or a presumed 
pathologic macrome1astasis based on fine needle aspiration biopsy with cytologicexamination. 
• 
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Appendix C: Department of Surgery Research Committee Approval 
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UNIVERSITY OF CAPE TOWN 
23rd October 2013 
Dr P Nashidengo 
Department of Surgery 
Division of General Surgery 
Groote Schuur Hospital 
University of Cape Town 
Dear Dr Nashidengo, 
Department of Surgery 
Departmental Research Committee 
Professor Anwar Suleman Mall 
J-45 Room Old Main Building, Groote Schuur Hospital, 
Observatory 7925, South Africa 
Tel (021) 406 6168/6232/6'227 Fax (021) 448 6461 
Eman: Anwar,Man@uct.ac.za 
RE: PROJECT 2013/119 
PROJECT TITLE: Five year review of breast-conserving therapy (BCT) for breast 
carcinoma: Surgical margins, re-excision and local recurrence in a single 
tertiary centre 
The above proposal was reviewed by the Department of Surgery Research Committee and I am pleased to inform you 
that the committee approved the study. 
Please use the above project number in all future correspondence. 
Yours sincerely 
PROFESSOR ANWAR S MALL 
CHAIRMAN: RESEARCH COMMITIEE 
"OUR MISSION is to be an outstanding teaching and research university, 
educating for life and addressing the challenges facing our society.· 
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16 April 2014 
HREC REF: 141/2014 
Dr L Cairncross 
Surgery/Endocrine Oncology 
J Floor 
0MB 
Dear Dr calrncross 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Old Main Building 
Groote Schuur Hospital 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
Email: 1amees.emjedl@uct.ac za 
Website: www health.uct.ac.za/research/humanethlcs/forms 
PROJECT TITLE: FIVE YEAR REVIEW OF BREAST-CONSERVING THERAPY (BCT) FOR BREAST 
CARCINOMA: SURGICAL MARGINS, RE-EXCISION AND LOCAL RECURRENCE IN A SINGLE 
TERTIARY CENTRE (MMed - Dr Pueya Nashidengo) 
Thank you for your response letter to the Faculty of Health Sciences Human Research Ethics 
Committee dated 23 March 2014. 
It is a pleasure to Inform you that the HREC has formally approved the above-mentioned study. 
Approval is granted for one year until the 30th April 2015. 
Please submit a progress form, using the standardised Annual Report Form if the study continues 
beyond the approval period. Please submit a Standard Closure form if the study is completed within 
the approval period. 
(Forms can be found on our website: www.health.uct.ac.za/research/humaneth jcs/forms) 
We acknowledge that the MMed student Dr Pueya Nashldengo will also be Involved In this 
study. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
Investigator. 
Yours sincerely 
PROFESSOR M LOCKMAN 
CHAIRPERSON. FHS HUMAN ETHICS 
Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of Cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Cl inical Research with a new drug in patients, based on the Medical 
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), International Convention on 
Harmonisation Good Clinical Practice (ICH GCP) and Declaration of Helsinki guidelines. 
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